s 20928 has been researched along with 13-hydroxy-9,11-octadecadienoic acid in 1 studies
| Studies (s 20928) | Trials (s 20928) | Recent Studies (post-2010) (s 20928) | Studies (13-hydroxy-9,11-octadecadienoic acid) | Trials (13-hydroxy-9,11-octadecadienoic acid) | Recent Studies (post-2010) (13-hydroxy-9,11-octadecadienoic acid) |
|---|---|---|---|---|---|
| 17 | 0 | 0 | 327 | 7 | 65 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blask, DE; Dauchy, RT; Holowachuk, EW; Kopff, HS; Ruhoff, MS; Sauer, LA | 1 |
1 other study(ies) available for s 20928 and 13-hydroxy-9,11-octadecadienoic acid
| Article | Year |
|---|---|
Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Biological Transport; Cell Division; Circadian Rhythm; Colforsin; Linoleic Acid; Linoleic Acids; Liver Neoplasms, Experimental; Male; Melatonin; Models, Biological; Naphthalenes; Perfusion; Pertussis Toxin; Rats; Rats, Inbred BUF; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Signal Transduction; Virulence Factors, Bordetella | 1999 |